Malone et al¹ performed a randomized trial comparing 6 months of neoadjuvant versus adjuvant androgen deprivation therapy (ADT) combined with dose-escalated radiation therapy (RT) in 432 patients with localized prostate cancer, with the primary end point being biochemical recurrence-free survival (bRFS). For RT, 76 Gy (prostate only) in 38 fractions was applied using image-guided three-dimensional conformal external beam RT. ADT consisted of an antiandrogen and a gonadotropin-releasing hormone agonist. Ninety-five percent of patients had intermediate-risk features. The 10-year bRFS rates were 80.5% versus 87.4% for the neoadjuvant and adjuvant trial arm, respectively, being not significantly different.

中文翻译：

---

中度局限性前列腺癌患者除确定性放射治疗外，还需要进行雄激素剥夺治疗。

Malone等人¹对432例局限性前列腺癌患者进行了6个月的新辅助疗法与辅助雄激素剥夺疗法（ADT）联合剂量递增放射疗法（RT）的随机对照试验，主要终点是无生化复发（bRFS）。对于RT，使用图像引导的三维共形外照射RT施加38个分数的76 Gy（仅前列腺）。ADT由抗雄激素和促性腺激素释放激素激动剂组成。95％的患者具有中等风险特征。新辅助和辅助试验组的10年bRFS发生率分别为80.5％和87.4％，无显着差异。